What is the 13F Pro Quality Score for ZURA?

13F Pro ranks Zura Bio Ltd (ZURA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ZURA's current score at https://13fpro.ai/research/ZURA (free sign-up required for the full ranking).

Which hedge funds own the most ZURA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ZURA include SUVRETTA CAPITAL MANAGEMENT,, VR Adviser,, GREAT POINT PARTNERS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ZURA as soon as new 13F filings post.

Where does 13F Pro source ZURA data?

All Zura Bio Ltd fundamentals and ownership data come directly from SEC EDGAR. Zura Bio Ltd files with the SEC under CIK 1855644. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ZURA in?

Zura Bio Ltd (ZURA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ZURA research updated on 13F Pro?

ZURA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Zura Bio Ltd(ZURA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1855644 ZURA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ZURA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Zura Bio Ltd (ZURA), a Healthcare sector company. ZURA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Zura Bio Ltd reports net income of $-24.2M, free cash flow of $-18.9M. Top institutional holders of ZURA by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT,, VR Adviser,, GREAT POINT PARTNERS, based on the most recent SEC filings. ZURA trades on the Nasdaq exchange and files with the SEC under CIK 1855644. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZURA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Zura Bio Ltd directly from SEC EDGAR.

Net Income

Q1 2026

$-24.2M

Free Cash Flow

Q1 2026

$-18.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-31.0% YoY

$-68.7MFY 2025

FY22 $-8.7MFY23 $-60.4MFY24 $-52.4MFY25 $-68.7M

Operating Income

-36.3% YoY

$-75.2MFY 2025

FY22 $-2.7MFY23 $-62.6MFY24 $-55.2MFY25 $-75.2M

EPS (Diluted)

-76.7% YoY

$-1.06FY 2025

FY22 $-141.97FY23 $-2.09FY24 $-0.60FY25 $-1.06

Total Assets

-36.5% YoY

$113.9MFY 2025

FY22 $5.3MFY23 $100.8MFY24 $179.5MFY25 $113.9M

Op. Cash Flow

-130.9% YoY

$-64.8MFY 2025

FY22 $-1.1MFY23 $-15.1MFY24 $-28.1MFY25 $-64.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Net Income	$-68.7M -31.0%	$-52.4M +13.2%	$-60.4M -593.8%	$-8.7M
Operating Income	$-75.2M -36.3%	$-55.2M +11.9%	$-62.6M -2241.5%	$-2.7M
EPS (Diluted)	$-1.06 -76.7%	$-0.60 +71.3%	$-2.09 +98.5%	$-141.97
Total Assets	$113.9M -36.5%	$179.5M +78.0%	$100.8M +1816.4%	$5.3M
Operating Cash Flow	$-64.8M -130.9%	$-28.1M -86.5%	$-15.1M -1305.6%	$-1.1M

AI Insight: ZURA Financial Trends

Zura Bio is a pre-revenue clinical-stage burner: equity has eroded from $157M to ~$102M over six quarters with no revenue in sight.

• Equity has declined steadily from $157M in Q2 2024 to $102M in Q4 2025, a $55M erosion in six quarters.

• Operating cash outflows accelerated sharply to -$22M in Q4 2025 and -$19M in Q1 2026, versus -$6M in Q3 2024.

• Operating losses widened to -$25M in Q1 2026, the largest single-quarter loss in the dataset.

⚠ Equity figure is absent in Q1 2026; with -$19M operating cash outflow, remaining runway is a critical near-term concern.

⚠ No debt is reported across all periods — watch for any new debt issuance or dilutive equity raise to fund operations.

AI Insight: ZURA Ratio Trends

ZURA's return metrics have deteriorated steadily since Q2 2024, with ROIC deepening from -30.0% to -72.5% by Q4 2025, signaling accelerating cash burn with no revenue offset.

• ROIC worsened from -30.0% in Q2 2024 to -72.5% in Q4 2025, a 42.5pp deterioration over six quarters.

• ROA declined from -21.8% in Q2 2024 to -60.3% in Q4 2025, reflecting deepening losses relative to asset base.

• ROE fell from -26.4% in Q2 2024 to -67.7% in Q4 2025, indicating equity is being consumed by mounting net losses.

⚠ OpMargin, NPM, and D/E are entirely absent across all periods — critical profitability and leverage data unavailable for full assessment.

⚠ ROA rebounded to -42.4% in Q1 2026 from -60.3% in Q4 2025 — monitor whether this easing persists or reverses.

⚠ No quarter shows any improvement in ROIC or ROE trend; sustained deterioration raises going-concern cash runway questions.

Get alerted when ZURA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Zura Bio Ltd including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ZURA

SUVRETTA CAPITAL MANAGEMENT, LLC
$53.9M9,067,001 sh
VR Adviser, LLC
$38.3M6,434,990 sh
GREAT POINT PARTNERS LLC
$25.1M4,215,930 sh
BRAIDWELL LP
$23.7M3,988,989 sh
Siren, L.L.C.
$22.2M3,734,866 sh
Commodore Capital LP
$19.3M3,250,000 sh
PFIZER INC
$16.8M2,838,913 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$16.4M2,750,000 sh
Affinity Asset Advisors, LLC
$15.3M2,564,303 sh
MILLENNIUM MANAGEMENT LLC
$9.0M1,508,063 sh

Fund	Value	Shares
SUVRETTA CAPITAL MANAGEMENT, LLC	$53.9M	9,067,001
VR Adviser, LLC	$38.3M	6,434,990
GREAT POINT PARTNERS LLC	$25.1M	4,215,930
BRAIDWELL LP	$23.7M	3,988,989
Siren, L.L.C.	$22.2M	3,734,866
Commodore Capital LP	$19.3M	3,250,000
PFIZER INC	$16.8M	2,838,913
ADAGE CAPITAL PARTNERS GP, L.L.C.	$16.4M	2,750,000
Affinity Asset Advisors, LLC	$15.3M	2,564,303
MILLENNIUM MANAGEMENT LLC	$9.0M	1,508,063

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ZURA on your watchlist

Track score changes the day Zura Bio Ltd files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ZURA a good stock to buy?

13F Pro's AI-powered analysis of Zura Bio Ltd (ZURA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ZURA are available on the ZURA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ZURA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ZURA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Zura Bio Ltd's investment landscape.